Regeneron granted FDA priority review for rare bone disorder therapy
Source: SeekingAlpha
2026-02-19 07:31:05 ET
More on Regeneron Pharmaceuticals
- Regeneron: Expect Double-Digit Growth In 2026
- Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript
- Regeneron Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation
- Regeneron outlines 18 new Phase III studies and expects four FDA approvals in 2026 while advancing EYLEA HD and DUPIXENT growth
- Regeneron posts Q4 beat as Sanofi collaboration offsets Eylea headwinds
Read the full article on Seeking Alpha
For further details see:
Regeneron granted FDA priority review for rare bone disorder therapy
Regeneron Pharmaceuticals Inc.
NASDAQ: REGN
REGN Trading
-3.4% G/L:
$754.90 Last:
201,922 Volume:
$764.06 Open:
REGN Latest News
March 12, 2026 04:04:00 am
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making
REGN Stock Data
$80,621,924,056
100,116,656
N/A
714
N/A
Biotechnology & Life Sciences
Healthcare
US
Tarrytown
